Health Economics›Peripheral T-cell lymphoma›Untreated randomized data

Untreated randomized data

Peripheral T-cell lymphoma · 5 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
BV-CHP Variant #01	—	R 85 921	21d	48.2 mo	—	70	R 6 014 481 PFS proxy	2
GDPT Variant #01	—	R 5 797	21d	—	—	—	—	—
CMED Variant #01	—	R 3 645	14d	—	—	—	—	—
CHOP-14 (Prednisolone) Variant #01	—	R 878	14d	—	—	—	—	—
CHOP Variant #13	—	R 859	21d	15.5 mo	—	23	R 19 749 PFS proxy	3

5 of 5 regimens shown